Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Alnylam's 'Day After' Revusiran Failure Bad, Maybe Not Catastrophic

Oct 06 2016

• By Joseph Haas

Desperate businessmen

Related Content

Alnylam Advancing From Platform Buzz To Late-Stage Clinical Work

Dec 21 2015

Alnylam's Fitusiran Could Provide Comprehensive Hemophilia Therapy Option

Aug 29 2016

Alnylam Ends Revusiran In Phase III, But Was Failure Due To Safety Or Efficacy?

Oct 06 2016

Alnylam, Medicines Company PCSK9 Drug Has Quarterly Dose Potential

Aug 30 2015

Related Companies

Alnylam Pharmaceuticals Inc.

Regulus Therapeutics Inc.

Dicerna Pharmaceuticals, Inc.

Ionis Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.

The Medicines Company

Additional Topics

Commercial Companies Drug Safety Innovation Platform Technologies Research & Development Cardiovascular

More from Business

More from Scrip

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.